It is important that experienced adverse events are reported after a medicinal product has been approved. This enables us as a pharmaceutical company to continuously monitor the benefit-risk relationship of the medicinal product.
We therefore urge consumers and healthcare professionals to report any suspected adverse events either to their local pharmaceutical authority in the country where the adverse event took place or directly to us at Glenmark Pharmaceuticals Nordic AB. See contact details below.
SWEDEN
Läkemedelsverket
Box 26
751 03 Uppsala
Webbplats: www.lakemedelsverket.se
DENMARK
Lægemiddelstyrelsen
Axel Heides Gade 1
DK-2300 København S
Websted: www.meldenbivirkning.dk
FINLAND
Lääkealan turvallisuus- ja kehittämiskeskus Fimea
Lääkkeiden haittavaikutusrekisteri
PL 55
00034 FIMEA
Verkkosivusto: www.fimea.fi
NORWAY
Statens legemiddelverk
Postboks 240 Skøyen
0213 Oslo
Nettsted: www.legemiddelverket.no
ICELAND
LYFJASTOFNUN
Vínlandsleið 14
113 Reykjavík
Vefsíðu: www.lyfjastofnun.is
Glenmark Pharmaceuticals Nordic AB via email to: or by phone: +46 40 35 48 10
We as a pharmaceutical company are not able to give specific advice on medical treatments. These questions should only be answered by health-care professionals.